Scholarlink

Background <p>Although immune checkpoint inhibitors (ICIs) have contributed to significant advances in the treatment of lung cancer, there is a lack of research investigating their efficacy in patients with non-small-cell lung cancer harboring <i>NRG1</i> fusion genes.</p> Methods <p>This retrospective study included data from patients diagnosed with <i>NRG1</i> fusion-positive NSCLC, who underwent ICI treatment at the Shanghai Pulmonary Hospital and Shanghai Changzheng Hospital (Shanghai, China) between 2016 and 2025, in accordance with the Response Evaluation Criteria for Solid Tumors, version 1.1.</p> Results <p>Data from 20 patients were analyzed. The total objective response rate was 15.0%, the disease control rate reached 65.1%, and the median progression-free survival (PFS) was 3.8&#xa0;months. Most patients (11/20 [61.5%]) underwent an immunological-chemotherapy combination regimen, with a PFS of 5.5&#xa0;months. Among the 8 patients who received ICIs as first-line treatment, 2 exhibited partial response, 5 had stable disease, and the median PFS was 4.8&#xa0;months. In the entire cohort, among the 5 patients who received ICIs before targeted drug therapy, the median PFS was 6.75&#xa0;months.</p> Conclusions <p>Results of this retrospective study provide clinical evidence supporting the merits of first-line ICI-based treatment(s) in patients diagnosed with <i>NRG1</i> fusion gene-positive NSCLC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical outcomes of immune checkpoint inhibitor based therapy in NRG1 fusion positive non small cell lung cancer a retrospective study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月3日

查看全文
  • Xiyun Yan,
  • Xiyan Fu,
  • Zhanghui Long,
  • Li Liu,
  • Yuansheng Zang,
  • Chunxia Su

摘要

Background

Although immune checkpoint inhibitors (ICIs) have contributed to significant advances in the treatment of lung cancer, there is a lack of research investigating their efficacy in patients with non-small-cell lung cancer harboring NRG1 fusion genes.

Methods

This retrospective study included data from patients diagnosed with NRG1 fusion-positive NSCLC, who underwent ICI treatment at the Shanghai Pulmonary Hospital and Shanghai Changzheng Hospital (Shanghai, China) between 2016 and 2025, in accordance with the Response Evaluation Criteria for Solid Tumors, version 1.1.

Results

Data from 20 patients were analyzed. The total objective response rate was 15.0%, the disease control rate reached 65.1%, and the median progression-free survival (PFS) was 3.8 months. Most patients (11/20 [61.5%]) underwent an immunological-chemotherapy combination regimen, with a PFS of 5.5 months. Among the 8 patients who received ICIs as first-line treatment, 2 exhibited partial response, 5 had stable disease, and the median PFS was 4.8 months. In the entire cohort, among the 5 patients who received ICIs before targeted drug therapy, the median PFS was 6.75 months.

Conclusions

Results of this retrospective study provide clinical evidence supporting the merits of first-line ICI-based treatment(s) in patients diagnosed with NRG1 fusion gene-positive NSCLC.